150 related articles for article (PubMed ID: 38630694)
21. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
Han YC; Kahler J; Piché-Nicholas N; Hu W; Thibault S; Jiang F; Leal M; Katragadda M; Maderna A; Dushin R; Prashad N; Charati MB; Clark T; Tumey LN; Tan X; Giannakou A; Rosfjord E; Gerber HP; Tchistiakova L; Loganzo F; O'Donnell CJ; Sapra P
Clin Cancer Res; 2021 Jan; 27(2):622-631. PubMed ID: 33148666
[TBL] [Abstract][Full Text] [Related]
22. Tumor Site-Specific Cleavage Improves the Antitumor Efficacy of Antibody-Drug Conjugates.
Xu K; Han J; Yang L; Cao L; Li S; Hong Z
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446189
[TBL] [Abstract][Full Text] [Related]
23. N-terminal selective conjugation method widens the therapeutic window of antibody-drug conjugates by improving tolerability and stability.
Ko MJ; Song D; Kim J; Kim JY; Eom J; Sung B; Son YG; Kim YM; Lee SH; You WK; Jung J
MAbs; 2021; 13(1):1914885. PubMed ID: 33904380
[TBL] [Abstract][Full Text] [Related]
24. Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors.
McDermott MSJ; O'Brien NA; Hoffstrom B; Gong K; Lu M; Zhang J; Luo T; Liang M; Jia W; Hong JJ; Chau K; Davenport S; Xie B; Press MF; Panayiotou R; Handly-Santana A; Brugge JS; Presta L; Glaspy J; Slamon DJ
Clin Cancer Res; 2023 Jun; 29(11):2131-2143. PubMed ID: 36884217
[TBL] [Abstract][Full Text] [Related]
25. Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.
DiPippo VA; Olson WC; Nguyen HM; Brown LG; Vessella RL; Corey E
Prostate; 2015 Feb; 75(3):303-13. PubMed ID: 25327986
[TBL] [Abstract][Full Text] [Related]
26. An Anti-CD22-
Yu SF; Lee DW; Zheng B; Del Rosario G; Leipold D; Booler H; Zhong F; Carrasco-Triguero M; Hong K; Yan P; Rowntree RK; Schutten MM; Pillow T; Sadowsky JD; Dragovich PS; Polson AG
Mol Cancer Ther; 2021 Feb; 20(2):340-346. PubMed ID: 33273056
[TBL] [Abstract][Full Text] [Related]
27. Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice.
Chang HP; Li Z; Shah DK
Pharm Res; 2022 Jan; 39(1):1-24. PubMed ID: 35044590
[TBL] [Abstract][Full Text] [Related]
28. Development of a MMAE-based antibody-drug conjugate targeting B7-H3 for glioblastoma.
Mao Y; Wei D; Fu F; Wang H; Sun Z; Huang Z; Wang Y; Zhang G; Zhang X; Jiang B; Chen H
Eur J Med Chem; 2023 Sep; 257():115489. PubMed ID: 37235999
[TBL] [Abstract][Full Text] [Related]
29. Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody-Drug Conjugates to Increase
Ponte JF; Lanieri L; Khera E; Laleau R; Ab O; Espelin C; Kohli N; Matin B; Setiady Y; Miller ML; Keating TA; Chari R; Pinkas J; Gregory R; Thurber GM
Mol Cancer Ther; 2021 Jan; 20(1):203-212. PubMed ID: 33177153
[TBL] [Abstract][Full Text] [Related]
30. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
[TBL] [Abstract][Full Text] [Related]
31. Microtubule and tubulin binding and regulation of microtubule dynamics by the antibody drug conjugate (ADC) payload, monomethyl auristatin E (MMAE): Mechanistic insights into MMAE ADC peripheral neuropathy.
Best RL; LaPointe NE; Azarenko O; Miller H; Genualdi C; Chih S; Shen BQ; Jordan MA; Wilson L; Feinstein SC; Stagg NJ
Toxicol Appl Pharmacol; 2021 Jun; 421():115534. PubMed ID: 33852878
[TBL] [Abstract][Full Text] [Related]
32. Anti-Lymphocyte Antigen 6 Complex, Locus E-
Yip V; Figueroa I; Latifi B; Masih S; Ng C; Leipold D; Kamath A; Shen BQ
Drug Metab Dispos; 2020 Dec; 48(12):1247-1256. PubMed ID: 33020064
[TBL] [Abstract][Full Text] [Related]
33. Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes.
Shor B; Kahler J; Dougher M; Xu J; Mack M; Rosfjord E; Wang F; Melamud E; Sapra P
Clin Cancer Res; 2016 Jan; 22(2):383-94. PubMed ID: 26319086
[TBL] [Abstract][Full Text] [Related]
34. Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin.
Li D; Lee D; Dere RC; Zheng B; Yu SF; Fuh FK; Kozak KR; Chung S; Bumbaca Yadav D; Nazzal D; Danilenko D; Go MAT; Williams M; Polson AG; Poon KA; Prabhu S
Br J Pharmacol; 2019 Oct; 176(19):3805-3818. PubMed ID: 31270798
[TBL] [Abstract][Full Text] [Related]
35. Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade.
Hooper AT; Marquette K; Chang CB; Golas J; Jain S; Lam MH; Guffroy M; Leal M; Falahatpisheh H; Mathur D; Chen T; Kelleher K; Khandke K; Muszynska E; Loganzo F; Rosfjord E; Lucas J; Kan Z; Subramanyam C; O'Donnell C; Neri D; Gerber HP; May C; Sapra P
Mol Cancer Ther; 2022 Sep; 21(9):1462-1472. PubMed ID: 35793468
[TBL] [Abstract][Full Text] [Related]
36. AGCM-22, a novel cetuximab-based EGFR-targeting antibody-drug-conjugate with highly selective anti-glioblastoma efficacy.
Li D; Sun X; Li Y; Shang C; Dong Y; Zhao R; Zhang H; Wang Z; Fan S; Ma C; Li X
Bioorg Med Chem; 2024 Mar; 102():117657. PubMed ID: 38428068
[TBL] [Abstract][Full Text] [Related]
37. A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate.
Xiao D; Zhao L; Xie F; Fan S; Liu L; Li W; Cao R; Li S; Zhong W; Zhou X
Theranostics; 2021; 11(6):2550-2563. PubMed ID: 33456559
[TBL] [Abstract][Full Text] [Related]
38. Site-Specific Conjugation of Monomethyl Auristatin E to Anti-CD30 Antibodies Improves Their Pharmacokinetics and Therapeutic Index in Rodent Models.
Lhospice F; Brégeon D; Belmant C; Dennler P; Chiotellis A; Fischer E; Gauthier L; Boëdec A; Rispaud H; Savard-Chambard S; Represa A; Schneider N; Paturel C; Sapet M; Delcambre C; Ingoure S; Viaud N; Bonnafous C; Schibli R; Romagné F
Mol Pharm; 2015 Jun; 12(6):1863-71. PubMed ID: 25625323
[TBL] [Abstract][Full Text] [Related]
39. Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate.
Panchamoorthy G; Jin C; Raina D; Bharti A; Yamamoto M; Adeebge D; Zhao Q; Bronson R; Jiang S; Li L; Suzuki Y; Tagde A; Ghoroghchian PP; Wong KK; Kharbanda S; Kufe D
JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925694
[TBL] [Abstract][Full Text] [Related]
40. Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.
Li F; Emmerton KK; Jonas M; Zhang X; Miyamoto JB; Setter JR; Nicholas ND; Okeley NM; Lyon RP; Benjamin DR; Law CL
Cancer Res; 2016 May; 76(9):2710-9. PubMed ID: 26921341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]